Zoltan B.
- Country
- Hungary
- Department
- II. Belgyógyászati Osztály
Research Overview
- Effect of Orforglipron on Major Adverse Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
- Phase 3 Randomized Double-Blind Placebo-Controlled Study of KAI-9531 in Adults With Obesity or Overweight and Diabetes
- Inclisiran for Prevention of Major Adverse Cardiovascular Events in High-Risk Primary Prevention Patients with Atherosclerotic Cardiovascular Disease
Data & Insights
Has run more than one trial at 413 of 743 partner sites.
Specializations
Cardiovascular Disease Prevention
Specializes in investigating therapeutic approaches for atherosclerotic cardiovascular disease (ASCVD) prevention, with particular focus on innovative treatments for high-risk patients. The investigator explores advanced interventions targeting major adverse cardiovascular events.
- Primary Prevention Strategies
- Cardiovascular Risk Management
- Novel Therapeutic Approaches
Metabolic Health
Focuses on the intersection of obesity management and cardiovascular health, investigating innovative therapeutic solutions for patients with complex metabolic conditions. Explores the relationship between weight management and cardiovascular outcomes.
- Obesity Treatment
- Cardiovascular Risk Reduction
- Metabolic Disease Management
Diabetes Care
Specializes in therapeutic approaches for Type 2 Diabetes Mellitus, particularly focusing on cardiovascular outcomes in diabetic patients. Investigates comparative effectiveness of different treatment modalities in managing diabetes-related cardiovascular complications.
- Diabetes Management
- Cardiovascular Risk Assessment
- Therapeutic Optimization
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.